 CSL Limiteds recent RD investor briefing suggests that the company has been able to build a strong RD pipeline without overspending. Separately, CSL Limited expects the top line of its recently acquired pharmaceuticals company to generate a reasonably good revenue CAGR above 10 for the midterm. 